TY - JOUR
T1 - Antitumor chemotherapy in combined treatment of patients with cancer of the larynx and hypopharynx
AU - Belevich, Yu V.
AU - Choinzonov, E. L.
AU - Goldberg, V. E.
AU - Chizhevskaya, S. Yu
AU - Frolova, I. G.
AU - Chernov, V. I.
AU - Startseva, Zh A.
AU - Goldberg, A. V.
AU - Kulbakin, D. E.
AU - Popova, N. O.
AU - Vysotskaya, V. V.
AU - Simolina, E. I.
AU - Dudnikova, E. A.
PY - 2018
Y1 - 2018
N2 - Preliminary results of the evaluation of the effectiveness of combined treatment of 116 patients with morphologically verified squamous cell carcinoma of the larynx and hypopharynx II-IV (T2-4N0-2M0) stages of the tumor process for the period from 2006 to 2017 are presented in the article. Patients of the study group (n=20) underwent 2 courses neoadjuvant chemotherapy according to the scheme: docetaxel + cisplatin, followed by radiotherapy in the mode of multifraction of a dose of 1,3 Gy 2 times a day and surgical treatment (according to indications). Patients included in the comparison group (n=96) underwent 2 courses of neoadjuvant chemotherapy according to the scheme: paclitaxel + carboplatin, followed by radiotherapy in the mode of multifractionation of a dose of 1,3 Gy 2 times a day and surgical treatment (according to indications). The overall effectiveness of the treatment in the study group was 90,3 ± 3,1% (complete regression - 49,4 ± 4,0%, partial regression - 40,9 ± 5,2%), in the comparison group - 81,3 ± 4,0% (complete regression - 34,4 ± 4,8%, partial regression - 46,9 ± 5,1%). Differences between groups are statistically significant (p = 0,001).
AB - Preliminary results of the evaluation of the effectiveness of combined treatment of 116 patients with morphologically verified squamous cell carcinoma of the larynx and hypopharynx II-IV (T2-4N0-2M0) stages of the tumor process for the period from 2006 to 2017 are presented in the article. Patients of the study group (n=20) underwent 2 courses neoadjuvant chemotherapy according to the scheme: docetaxel + cisplatin, followed by radiotherapy in the mode of multifraction of a dose of 1,3 Gy 2 times a day and surgical treatment (according to indications). Patients included in the comparison group (n=96) underwent 2 courses of neoadjuvant chemotherapy according to the scheme: paclitaxel + carboplatin, followed by radiotherapy in the mode of multifractionation of a dose of 1,3 Gy 2 times a day and surgical treatment (according to indications). The overall effectiveness of the treatment in the study group was 90,3 ± 3,1% (complete regression - 49,4 ± 4,0%, partial regression - 40,9 ± 5,2%), in the comparison group - 81,3 ± 4,0% (complete regression - 34,4 ± 4,8%, partial regression - 46,9 ± 5,1%). Differences between groups are statistically significant (p = 0,001).
KW - Cancer of the larynx and hypopharynx
KW - Combined modality treatment
KW - Multifraction radiation therapy
KW - Neoadjuvant chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=85059769631&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059769631&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:85059769631
VL - 64
SP - 607
EP - 611
JO - Voprosy Onkologii
JF - Voprosy Onkologii
SN - 0507-3758
IS - 5
ER -